z-logo
open-access-imgOpen Access
Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy
Author(s) -
Kambayashi Yumi,
Ohuchi Kentaro,
Chiba Hiromu,
Tamabuchi Erika,
Nagasawa Tasuku,
Asano Yoshihide,
Fujimura Taku
Publication year - 2022
Publication title -
case reports in oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.365
H-Index - 19
ISSN - 1662-6575
DOI - 10.1159/000524013
Subject(s) - case report
Encorafenib plus binimetinib combination therapy is one of the first-line therapies for advanced melanoma, and it is known to cause a different profile of adverse events (AEs) than dabrafenib plus trametinib combination therapy. Of such AEs, tubulointerstitial nephritis caused by BRAF plus MEK inhibitors combination therapy is limited. In this report, a case of tubulointerstitial nephritis that developed in a rheumatoid arthritis patient with advanced melanoma treated with encorafenib plus dabrafenib combination therapy is presented.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here